Plethora Solutions Holdings plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical treatments for premature ejaculation in the area of men's sexual health. The Company is engaged in the development of new pharmaceutical products, which it refers to as Plethora Development. The Company has developed PSD502, which is a treatment for premature ejaculation, and has also completed phase III clinical trials. The PSD502 is also authorized to be marketed under the name of Prilocaine Lidocaine Plethora through the European Medicines Agency (EMA). Its subsidiaries include Plethora Solutions Limited and Plethora Therapeutics Limited.